BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22815137)

  • 1. Sorafenib combined with locoregional therapy prior to liver transplantation for hepatocellular carcinoma: an update on a previous case report.
    Vagefi PA; Hirose R
    J Gastrointest Cancer; 2013 Jun; 44(2):246-7. PubMed ID: 22815137
    [No Abstract]   [Full Text] [Related]  

  • 2. Sorafenib plus cisplatin for hepatocellular carcinoma.
    Brower V
    Lancet Oncol; 2016 Oct; 17(10):e424. PubMed ID: 27617663
    [No Abstract]   [Full Text] [Related]  

  • 3. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
    Zavaglia C; Airoldi A; Mancuso A; Vangeli M; ViganĂ² R; Cordone G; Gentiluomo M; Belli LS
    Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete Regression of Recurrent Advanced Hepatocellular Carcinoma After Liver Transplantation in Response to Sorafenib Treatment: A Case Report.
    Lee HY; Yang KH; Choi BH; Park YM; Yoon KT; Ryu JH; Chu CW
    Transplant Proc; 2016; 48(1):247-50. PubMed ID: 26915876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocellular carcinoma: sorafenib before liver transplantation?
    Braillon A
    Hepatology; 2010 Jun; 51(6):2232-3. PubMed ID: 20041410
    [No Abstract]   [Full Text] [Related]  

  • 6. Treating advanced hepatocellular carcinoma: How to get out of first gear.
    Harding JJ; Abou-Alfa GK
    Cancer; 2014 Oct; 120(20):3122-30. PubMed ID: 24898783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained remission over 36 months of advanced hepatocellular carcinoma after short-term sorafenib therapy.
    Ahn SY; Lee HS; Kweon YO; Tak WY; Park SY
    Dig Dis Sci; 2013 May; 58(5):1428-32. PubMed ID: 23306847
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
    Cho Y; Lee JH; Lee DH; Cho EJ; Yu SJ; Yi NJ; Lee KW; Kim YJ; Yoon JH; Suh KS
    Oncotarget; 2017 Jul; 8(29):47555-47564. PubMed ID: 28548930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].
    Ikeda M; Mitsunaga S; Shimizu S; Ohno I; Takahashi H; Okuyama H; Kuwahara A; Okusaka T
    Nihon Shokakibyo Gakkai Zasshi; 2012 Aug; 109(8):1346-54. PubMed ID: 22863957
    [No Abstract]   [Full Text] [Related]  

  • 10. Tolerability of single-agent sorafenib in the treatment of elderly patients with hepatocellular carcinoma (HCC).
    Francini E; Bianco V
    Hepatology; 2014 Aug; 60(2):764-5. PubMed ID: 25187926
    [No Abstract]   [Full Text] [Related]  

  • 11. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study.
    Liu Y; Yue H; Xu S; Wang F; Ma N; Li K; Qiao L; Wang J
    Int J Clin Oncol; 2015 Oct; 20(5):952-9. PubMed ID: 25712158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma.
    Garuti F; Camelli V; Spinardi L; Bucci L; Trevisani F
    Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 27079903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of dynamic contrast-enhanced ultrasound in HCC: prediction of response to a new combination therapy of sorafenib and panobinostat in advanced hepatocellular carcinoma.
    Knieling F; Waldner MJ; Goertz RS; Strobel D
    BMJ Case Rep; 2012 Dec; 2012():. PubMed ID: 23257272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma.
    Takeyama H; Beppu T; Higashi T; Kaida T; Arima K; Taki K; Imai K; Nitta H; Hayashi H; Nakagawa S; Okabe H; Hashimoto D; Chikamoto A; Ishiko T; Tanaka M; Sasaki Y; Baba H
    Surg Today; 2018 Apr; 48(4):431-438. PubMed ID: 29110089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
    You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
    J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.
    Matsuda Y; Ichida T; Fukumoto M
    Med Mol Morphol; 2011 Sep; 44(3):117-24. PubMed ID: 21922382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib in advanced hepatocellular carcinoma.
    Palmer DH
    N Engl J Med; 2008 Dec; 359(23):2498; author reply 2498-9. PubMed ID: 19065750
    [No Abstract]   [Full Text] [Related]  

  • 18. Abdominal aortic dissection during sorafenib therapy for hepatocellular carcinoma.
    Xu L; Wang B; Ding W
    Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):e24-e25. PubMed ID: 28163072
    [No Abstract]   [Full Text] [Related]  

  • 19. AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma.
    Altayar O; Shah R; Chang CY; Falck-Ytter Y; Muir AJ
    Gastroenterology; 2022 Mar; 162(3):937-951. PubMed ID: 35210015
    [No Abstract]   [Full Text] [Related]  

  • 20. [Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma].
    Yamashita T; Kaneko S
    Nihon Shokakibyo Gakkai Zasshi; 2012 Aug; 109(8):1335-45. PubMed ID: 22863956
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.